Press Coverage

Hepatitis C Treatment: Study Finds No Liver, Kidney or Cardiovascular Adverse Effects

Interview mentions that an ISMP QuarterWatchTM report raising questions about whether direct acting antiviral medications for the treatment of Hepatitis C posed any significant safety risks for patients was the impetus for further study.

For the full text, visit MedicalResearch.com online.

More News

Since COVID-19 vaccines were granted emergency use authorization, The Institute for Safe Medication Practices (ISMP) has received reports of errors related to storage, preparation, and administration. Because COVID-19 vaccine errors can result in reduced effectiveness, and other safety implications